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Many head-and-neck cancer (HNC) patients treated with radiotherapy suffer sig-
nificant anatomical changes due to tumor shrinkage or weight loss. The purpose of 
this study was to assess dose changes over target volumes and organs at risk during 
intensity-modulated radiotherapy for HNC patients. Sixteen HNC IMRT patients, 
all requiring bilateral neck irradiation, were enrolled in the study. A CTplan was 
performed and the initial dose distribution was calculated. During the treatment, 
two subsequent CTs at the 15th (CT15) and 25th (CT25) fractions were acquired. 
The initial plan was calculated on the CT15 and CT25, and dose-volume differences 
related to the CTplan were assessed. For target volumes, mean values of near-
maximun absorbed dose (D2%) increased at the 25th fraction, and doses covering 
95% and 98% of volume decreased significantly at the 15th fraction. Contralateral 
and ipsilateral parotid gland mean doses increased by 6.1% (range: -5.4, 23.5%) 
and 4.7% (range: -9.1, 22.3%), respectively, at CT25. The D2% in the spinal cord 
increased by 1.8 Gy at CT15. Mean absorbed dose increases at CT15 and CT25 were 
observed in: the lips, 3.8% and 5.3%; the oral cavity, 3.5% and 2.5%; and lower 
middle neck structure, 1.9% and 1.6%. Anatomical changes during treatment of 
HNC patients affect dose distribution and induce a loss of dose coverage to target 
volumes and an overdosage to critical structures. Appropriate organs at risk have 
to be contoured and monitored in order to know if the initial plan remains suitable 
during the course of the treatment. Reported dosimetric data can help to identify 
patients who could benefit from adaptive radiotherapy.
PACS numbers: 87.53.Kn, 87.55.Dk
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I. InTRoDucTIon
The benefit of intensity-modulated radiation therapy (IMRT) in the treatment of head-and-neck 
cancer (HNC) has been demonstrated in numerous studies.(1-3) Highly conformal radiation 
allows for a high dose to high-risk areas, whilst sparing adjacent organs at risk (OAR) such 
as the parotid glands. Clinical studies have shown that IMRT reduces grade-3 xerostomia in 
comparison to three-dimensional conformal radiotherapy (3D CRT).(4,5) For that reason, IMRT 
has become the standard treatment in many centers. IMRT dose distributions, with steep dose 
gradients, are very sensitive to geometrical uncertainties, and hence, deviations between planned 
and delivered dose distributions have to be minimized. One way of improving the treatment 
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accuracy is to reduce geometrical errors. Rigid errors, such as setup, have been extensively 
studied. Mechalakos et al.(6) for instance evaluated the interfraction and intrafraction errors 
in treatments of HNC and compared their results with previous studies from others authors. 
Margins are added to clinical volumes in order to take into account geometrical uncertainties. 
These planning margins are commonly calculated from measured systematic and random geo-
metrical errors.(7)    
However, it is well known that many HNC patients treated with radiotherapy (RT) suf-
fer significant anatomical changes due to tumor shrinkage or weight loss. Several scheduled 
rescanning studies have evaluated these volumetric changes in both target volumes and 
normal tissues,(8-11) mostly on the parotid glands and their consequent effects on dose 
distribution.(12-15) The information obtained from these studies indicates that anatomical 
changes during the treatment can cause deviations between the planned and delivered dose, 
specifically reducing dosage to target volumes whilst increasing dosage to critical structures.
Adaptive RT based on replanning during treatment is a common strategy to minimize the 
effect of anatomical changes over dose distribution,(16,17) although identifying which patients 
in particular could best benefit from replanning is, as yet, undetermined. Ahn et al.(18) indicated 
the need for an accurate determination of anatomical changes and their consequent dosimetric 
parameters as a prime factor in the determination of any subsequent replanning.
The purpose of the present study was to analyze volume variation repercussions on the 
dose distribution in both PTVs and organs at risk. The use of IMRT implies the irradiation of 
more OARs than conventional 3D CRT. Therefore, beside typical susceptible organs such as 
the eyes, spinal cord, parotid glands, and mandible, we have also included additional OARs 
such as the oral cavity, cochleae, lips, brain, brainstem, and lower middle neck structures. 
The influence of anatomical changes over dose distribution on these structures has not, until 
now, been reported in previous studies. The study was experimental and patients were treated 
without replanning.
 
II. MATERIALS AnD METHoDS
A. Eligibility criteria
Patients were required to have a histologically proven diagnosis of HN squamous cell carcinoma 
of the head and neck, staged T3-T4 N0 or T1-T4 N1-N3. Patients were aged 18 years or over, 
with a Karnofsky performance score of ≥ 80%. Eligibility criteria also included bilateral neck 
irradiation. The protocol was approved by the local Ethics Committee. All enrolled patients 
signed an informed consent form.
B.  cT acquisition and contouring
CT scans were made using a LightSpeed RT 4s helical CT model (GE, Tokyo, Japan) with 
2.5–5 mm slice spacing. Patients were in the supine position and immobilized with a ther-
moplastic head–shoulder mask accommodated on a VersaBoard immobilizer device (JRT 
Associates, Elmsford, NY). A planning CT scan (CTplan) was acquired one week before RT 
treatment. Second and third CT scans were performed during the course of treatment at the 
15th (CT15) and 25th (CT25) fractions. Patient weight was recorded before treatment and at 
weekly intervals during therapy.
The Eclipse version 7.5 (Varian Oncology Systems, Palo Alto, CA) treatment planning 
system was used for delineation and dose distribution calculations. Target volumes and normal 
tissues were manually contoured by a physician on each axial slice of the CTplan using MRI 
or contrast-enhanced CT. The definition of volumes was in accordance with ICRU Reports 
50-62,(19,20) but dose-volume parameters were reported according to the new ICRU Report 
83(21) IMRT recommendations. Gross tumor volume (GTV) included the primary tumor and 
affected lymph nodes. The GTV was expanded to include the high-risk regions (CTV2) and 
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the low risk nodal regions (CTV1). To compensate for geometrical uncertainties such as setup 
and organ motion, a 5 mm margin was automatically added to CTVs to obtain the planning 
target volume (PTV). In order to avoid dose compensation in the build-up region, in cases with 
no skin infiltration, the PTVs were manually modified excluding areas where the distance to 
the skin was less than 3 mm. Although these modified PTVs were used during optimization 
process, the absorbed dose was reported over the whole PTV. Prescribed doses were between 
51–54 Gy for PTV1 and 66–70 Gy for PTV2.
The critical structures contoured were: the parotid glands, spinal cord, mandible, eyes, oral 
cavity, brainstem, lips, cochleae, brain, and lower middle neck structures comprising the pha-
ryngeal constrictors, glottic-supraglottic larynx, and the esophagus. To avoid conflict between 
planning aims when OARs overlapped with PTVs, the former OARs were then automatically 
recontoured, excluding the region within PTV. The modified OARs were used in the optimiza-
tion process, but the final OAR dose goals were evaluated in the entire OAR. 
A limited external volume structure was contoured, representing the volume inside the ex-
ternal body contoured from the upper level of the PTV1 to the upper neck treatment area, thus 
avoiding the presence of the shoulders. This volume was added with the intention to correlate 
anatomical changes inside the treatment area with any weight change.   
         
c.  Treatment planning
IMRT treatment plan was generated on the CTplan with seven or nine 6 MV fields, using the 
simultaneous integrated boost (SIB) technique, treating the entire neck with IMRT but avoid-
ing matching fields.(22) The IMRT plans were optimized using an inverse planning algorithm, 
namely Helios 8005 (Varian Oncology Systems). The final dose distribution was calculated 
using the Pencil Beam Convolution 8005 with heterogeneity correction and 5 mm grid resolu-
tion. Optimization goals were as follows: 1) prescription doses (Dpres) must encompass at least 
95% of target volumes; 2) near-minimum absorbed doses (D98%) of PTVs should be higher 
than 93% of Dpres; 3) the near-maximum absorbed dose (D2%) of the PTVs should be less than 
115% of Dpres; 4) PTV2 should be considered as the highest priority target volume. 
High priority constraints to normal critical structures were: no more than 1.0 cm3 of spinal 
cord could receive more than 48 Gy; 2) no more than 1% of brainstem could receive more 
54 Gy; 3) D2% for mandible should be less than 70 Gy; 4) the parotid gland volume receiving 
26 Gy should be less than 50% in at least one gland; 5) D2% of normal tissue should be less 
than Dpres. 
Low priority constraints that should not compromise target coverage were: 1) the mean 
absorbed dose (Dmean) covering lower middle neck, oral cavity, and lips should be less than 
40 Gy; 2) eyes D2% should be less than 50 Gy; 3) cochleae D2% should be less than Dpres.
All patients were treated with a Clinac 2100 accelerator (Varian Oncology Systems) with 
Millenium MLC - 80 leaves of 1 cm width in a Dynamic mode. In order to reduce systematic 
setup errors, portal images were acquired periodically, and corrections were made using a 
weekly offline protocol. 
D.  Manual adaptive contouring 
A simplified methodology was designed to evaluate volume variation during treatment with no 
attempt to modify the initial PTVs. CT15 and CT25 were registered using the initial reference 
marks and bony anatomy. 
All contoured structures of CTplan were copied on the CT15 and CT25. Following this, all 
contours were manually adapted for any anatomical changes.
For PTVs, efforts were made to maintain the original clinical volumes, and were modified 
only to be consistent with the new anatomy — for instance, in cases where PTV extended 
beyond the skin or overlap areas limited by bones such as mandible and vertebra. We are well 
aware that PTV changes during the course of RT could arise both from anatomical variations 
and from clinical response (i.e., shrinkage and/or chemotherapy). Although the exact PTV in 
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each stage of the treatment remains a controversial subject, we had chosen this particular con-
touring methodology because the idea of the study was to assess only dose variations arising 
from anatomic changes and not from a clinical response. This methodology was used previ-
ously by other authors.(16)
In order to eliminate differences in volumes due to interobserver variability, the three scans 
of each patient were contoured by the same physician.  
The initial plan was calculated at the CT15 and CT25 and dose-volume differences related to 
CTplan were assessed on PTVs and organs at risk.
E.  Statistical analysis 
Comparisons of dose-volume parameters were assessed among all three CTs. Correlation 
between volume changes and weight loss was evaluated. All dose-volume parameters were 
reported following the ICRU 83 recommendations. The analyzed variables for GTV and PTV 
were: 1) volume, and 2) D2%, D98%, and D50%. For OARs, the studied variables were: 1) volume, 
and 2) D2%, Dmean, and 3) volume receiving absorbed dose D (VD), where D is the absorbed 
dose which, if exceeded within some volume, has a high probability of causing a serious 
complication. D is specifically defined for each structure. A random effects model for repeated 
measurements was fitted to assess differences between the planning CT and later CTs. A value 
of p <0.05 was considered significant.
All analyses were performed with STATA 10.1 (StataCorp. 2009. Statistical Software: 
 Release 10.1. College Station, TX).
 
III. RESuLTS 
A.  Patient characteristics
Between November 2008 and March 2010, a total of 16 patients with bilateral neck and 
supraclavicular nodes treated with IMRT were included. Table 1 shows patient characteris-
tics. Fourteen patients received radical treatment consisting of IMRT 70 Gy in 33 fractions 
of 2.12 Gy/fr, and systemic therapy specifically, Cisplatin for 13 of them (100 mg/m2; 
days 1, 22, 43) and a weekly administration of Cetuximab (anti-EGFR) for the remaining 
 patient. Two patients received postoperative IMRT with 64.5–66 Gy in 30–33 fractions of 
2.15–2 Gy/fr, respectively.
Table 1. Patients’ characteristics.
   N %
Age  Mean (range) 16 58 (29-77) years
Gender Male 10 62.5
  Female 6 37.5
Primary site Nasopharynx 1 6.3
  Oropharynx 7 43.8
  Oral Cavity 5 31.3
  Hypopharynx 1 6.3
  Unknown 2 12.5
T Stage Tx 2 12.5
  T1-T2 5 31.3
  T3 4 25.0
  T4 5 31.3
N Stage N0 3 18.8
  N1 2 12.5
  N2 10 62.5
  N3 1 6.3
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B.  Volume and weight changes
The average relative weight loss with regard to the initial weight was statistically significant, 
with a reduction of 3% (p = 0.0009) and 4.5% (p = < 0.0001) for CT15 and CT25, respectively. 
One of the patients showed a weight gain of 5.5% at CT15 and 7% at CT25. A new mask was 
required at CT15 due to this increase. 
Significant changes were found at the limited external volume, with an average decrease 
of 3% on both CTs (a range of: -16.3 to 12.9 for CT15 and -16.4 to 11.1 for CT25), with the 
maximum values corresponding to the sole patient with weight gain. Correlation between the 
weight change and the limited external volume variations was significant, with p = 0.006 for 
CT15 and p = 0.001 for CT25 with respect to the CTplan.
One patient showed an important decrease in their limited external volume without weight 
loss (i.e., due exclusively to tumor shrinkage). Of the remaining patients, 10 (63%) exhibited 
weight loss which was more significant at CT25 than at CT15, and 4 (25%) suffered weight loss 
during the three first weeks, after which their weights remained stable.
Differences between the initial average volumes measured at CTplan and the two subsequent 
CTs were assessed for target volumes and OARs. For target structures, only PTV2 had a sig-
nificant volume decrease of 13% (range: -58.2, 20.7) at the CT25. 
The parotid glands showed a progressive mean volume reduction of 22% at CT15 and 30% at 
CT25, corresponding to a mean reduction of 1.4% per treatment day (td). No other OAR showed 
a significant volume variation. Mean volumes, averaged over the 16 patients, and p values are 
shown on Table 2 for the PTVs and the OARs with statistically significant changes only.
Table 2. Volumes with significant changes on CT15 and CT25 in relation to CTplan.
  Limited External Contralateral Ipsilateral
 PTV2 Contour Parotid Gland Parotid Gland
  Meana (SD) p Mean (SD) p Mean (SD) p Mean (SD) p
CTplan 130.8 (73.1)  1692 (412)  18.71 (10.3)  19.2 (10.6)
CT15 116.7 (54.8) 0.07 1639 (402) 0.017 14.2 (6.6) <0.001 15.3 (8.3) 0.003
CT25 113.6 (53.5) 0.03 1638 (415) 0.014 13.1 (6.4) <0.001 13.5 (7.2) <0.001
a The mean value is the average volume between 16 patients, in cm3.
SD is the standard deviation; p < 0.05 is statistically significant.
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c.  Dosimetric changes on target volumes
Table 3 shows target volume averaged dose parameters at CTplan, CT15, and CT25. Values are 
presented as a percentage of Dpres of each PTV. Average D2% values increased in all target vol-
umes, with the most significant increase seen at CT25. In contrast, the dose covering the 95% 
and 98% of the volume decreased significantly at CT15 for PTV2 and in both CTs for PTV1.
Table 3. Averaged dose-volume parameters on CTplan, CT15, and CT25 for target volumes.
 
Target
 D2% D50% D95% D98%
 Volume  Mean
a (SD) p Mean (SD) p Mean (SD) p Mean (SD) p
GTV CTplan 111.4 (3)  107.1 (2.5)  103.7 (2)  103.0 (1.7)
  CT15 112.6 (3.7) 0.145 107.7 (2.7) 0.094 103.3 (2.8) 0.491 101.2 (4.3) 0.158
  CT25 113.7 (4.7) 0.006 108.2 (2.7) 0.001 104.3 (2.5) 0.375 103.4 (2.5) 0.616
PTV2 CTplan 110.3 (3.1)  105.1 (1.7)  100 (0)  97.6 (1.3)
  CT15 112.1 (4.6) 0.036 105.1 (2.7) 0.913  96.4 (7) 0.012 92.0 (9.3) 0.003
  CT25 112.6 (4.7) 0.008 105.8 (2.3) 0.109  98.9 (3.6) 0.414 95.8 (5) 0.348
PTV1 CTplan 127.0 (6.4)  111 (4.5)  101.2 (3)  98.2 (2.8) 
  CT15 130.0 (6.9) <0.001 111.3 (5.7) 0.615  96.7 (6.7) 0.05 90.3 (11) 0.002
  CT25 130.8 (6.8) <0.001 111.6 (5.5) 0.373  97.1 (7) 0.01 91.5 (11) 0.008
a All values are averaged percentages of Dpres for each PTV and standard deviation (SD). DV absorbed dose that covers 
the fractional volume V. A value of p < 0.05 is statistically significant. The prescribed volume was 95% of PTV2 
so D50% values are higher than D95% . For PTV1, D50% and D2% are high because of the influence of high dose areas 
close to PTV2.
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D.  Dosimetric changes on organs at risk
Table 4 summarizes dose distribution changes on OAR, which showed some significant varia-
tion between planning CT and CT15 and CT25. All reported doses were percentages of Dpres. 
For the ipsilateral parotid gland, there was a Dm and V26Gy significant increase at the CT25 of 
4.7% and 6.3%, respectively. For the contralateral parotid gland, there were significant CT15 
and CT25 increases in the following: Dm (3.6% and 6.1%); D2% (5.9% and 7.7%), and in the 
V26Gy (7.4% and 10.4 %). For the spinal cord, the most notable dose increase was observed at 
CT15, measuring a D2% increase of 2.5% or 1.8 Gy. 
Mean absorbed doses increased at CT15 and CT25 in the following structures: the lips (3.8%, 
5.3%), the oral cavity (3.5%, 2.5%), and lower middle neck structures (1.9% and 1.6%). For 
lips, V20Gy increased in both CTs by 6.7% and 7.1%, respectively. V40Gy increased in CT15 and 
CT25 in the following organs: the oral cavity (5.7% and 3.3%), and lower middle neck structures 
(5.4% and 3.7%). No significant dose changes were found in the remaining OARs, namely the 
eyes, cochlea, brainstem, and brain.
No significant correlation was found between target and OAR dose increases with neither 
patient weight loss nor volume changes.
 
Table 4. Organs at risk with statistically significant dose changes between planning CT, CT15, and CT25.
 
Normal 
 D2%   Dmean  V
b
D
 Structure  Meana  (SD) p Mean (SD) p Mean (SD) p
Ipsi  Parotid  CTplan 89.7 (9.7)  44.5 (6.3)  49.7 (15.7)
Gland CT15 90.5 (12.5) 0.760 47.0 (10.9) 0.188 52.7 ( 20.3) 0.285
D = 26Gy CT25 93.8 (10.6) 0.102 49.2 (11.1) 0.012 56 (19.7) 0.024
Contra Parotid CTplan 80.7 (11.3)  42.8 (5.2)  48.2 (10.4)
Gland CT15 85.5 (9.2) 0.045 46.4 (6.3) 0.051 55.6 (11) 0.041
D = 26 Gy CT25 86.9 (12.8) 0.009 48.9 (8.2) 0.001 58.6 (14.4) 0.004
Mandible CTplan 100.2 (5.8)  64.3 (5.7)  9.8 (8.9)
D = 66 Gy CT15 101 (5.8) 0.148 64.7 (6) 0.445 10.6 (9.3) 0.35
 CT25 101.9 (5.7) 0.003 64.9 (6.6) 0.293 11.2 (9.3) 0.091
Oral Cavity CTplan 90.8 (10.1)  63.8 (14.1)  56.5 (25.1)
D =40 Gy CT15 94.5 (9.7) <0.001 67.3 (14.2) 0.001 62.3 (22.4) 0.004
 CT25 92.9 (10.3) 0.016 66.2 (14.7) 0.006 59.8 (25.4) 0.098
Middle low  CTplan 87.8 (10.6)  63.3 (8.2)  60.3 (24.3)
neck CT15 91.3 (12) 0.035 65.2 (8.1) 0.01 65.7 (22.7) 0.001
D = 40 Gy CT25 89.7 (13.2) 0.252 64.9 (8.7) 0.031 64.0 (22.5) 0.024
Lips CTplan 63.1 (16.8)  42.4 (11.4)  81.5 (16.5)
D = 20 Gy CT15 67.9 (17) 0.009 46.2 (13.4) 0.003 88.2 (15.8) 0.01 
 CT25 68.4 (19.5) 0.003 48.4 (14.5) <0.001 88.6 (13.5) 0.006
Spinal cord CTplan 62.9 (3.5)    0.0 (0)
D = 48 Gy CT15 65.4 (7.2) 0.021   0.3 (1) 0.01
 CT25 64.8 (5.2) 0.091   0.2 (0.4) 0.013
a The mean value is the average data between 16 patients and SD is the standard deviation. DV represents the absorbed 
dose that covers the fractional volume V, and is expressed as a % of the prescribed dose.
b VD means percentage of total volume receiving a D dose. For spinal cord volume it is in cc. A value of p < 0.05 is 
statistically significant.
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IV. DIScuSSIon
A limitation of our work is the difficulty to separate influences over dose distribution due to 
rigid errors (i.e., interfractional setup and intrafractional variations), and nonrigid anatomical 
changes during the course of the treatment. Additionally, our results have to be interpreted 
with a degree of caution as some of the dose variations with respect to the initial plan are small 
and can therefore be affected by other variables, such as calculation grid size and random co-
registration variability in the CTs.(23) Finally, although statistical models attempt to reduce the 
impact of extreme variations, such as the patient who gained weight in this study, the sample 
size can significantly affect results, as any variation will have more influence in a smaller 
sample. Despite the limited number of patients entered in our study (16), an important part of 
our results were nevertheless statistically significant. Furthermore, our sample size is also larger 
than most used in published works related  to this topic — for example, studies carried out by 
Barker et al.,(8) Hansen et al.,(16) Robar et al.,(13) Lee et al.,(11,15) and Castadot et al.(9) included 
14, 13, 15, 10, and 10 patients, respectively. Taking into account all of the above factors, the 
average data shown in Tables 3 and 4 could therefore help to identify dosimetric variables at 
risk of suffering changes during patient radiation treatment. 
The study shows that HNC patients treated with IMRT undergo weight changes correlated 
with limited external volume variations, suggesting that patient weight may be a reliable pa-
rameter to detect changes in irradiated body areas. Weight loss is appreciable after the third 
week of RT treatment.
Despite attempts being made to maintain the original PTVs size, volume change was 
significant in PTV2 because, in many cases, volumes lying beyond the external contour had 
been modified.
The target coverage loss during the first part of the treatment, in which no significant target 
volume changes occurred, can be related to the anatomical changes observed (i.e., changes in 
the external volume). Our results coincide with Ahn et al.,(18) who studied 23 HNC patients 
undergoing regular scans and found a loss of PTV coverage at approximately the 11th fraction, 
which was recovered in the posterior scans. 
The parotid glands suffered a significant volume reduction and dose increase as treatment 
advanced. We show a significant averaged increase in Dmean in the parotid glands of 5.4% 
(3.8 Gy) at the 25th fraction, consistent with Lee et al.,(15) who reported a difference between 
planned and received mean doses of less than 10% in 70% of studied patients. In our study, the 
parotid glands suffered a mean reduction of 1.4%/td, consistent with 1.5%/td in the study by 
Bhide et al.,(12) although a little higher than Castadot et al. and Lee et al.(9,15) of 0.9%–1.0%/td. 
No correlation was found between volume reduction and dose. This may be due to one of many 
factors including a potential medial translation of the glands into high-dose areas, as reported 
by several authors.(8,9,11) 
None of the remaining normal tissues studied suffered volume variations. Nonetheless, the 
spinal cord and mandible showed a D2% increase. The oral cavity, lips, and lower middle neck 
structures suffered a mean dose increase significant in the two CTs, indicating that body volume 
reduction inside the treatment area most likely contributed to a dose increase. Dose variation 
over these structures should therefore be considered.
For HNC patients treated with 3D CRT, except in the case of larynx and hypopharynx  tumors, 
a central block is usually employed in the anterior neck field in order to avoid dysphasia and 
swallowing problems related with middle neck structure irradiation. In this study, lower middle 
neck structures were included because treating the entire neck with IMRT nonmatching fields 
decreases the risk of hot or cold spots due to errors in collimator positioning, while at the 
same time increases the dose in the lower middle neck.(24) In our statistical data, the volume 
of middle neck structures receiving more than 40 Gy was significantly increased in both CTs 
with an average increment of 4.6%. 
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Dose deviations in relation to the initial dose in organs such as the oral cavity, lips, and middle 
lower neck have not yet been studied, and we think therefore that it is of interest to evaluate the 
effect of the above deviations on patients entered in our study. Table 5 shows the dose variation 
range of Dmean and VD with respect to initial dose in the aforementioned structures in 16 of 
the patients. The number of patients with dose increments up to 10% is reported; the number 
in parenthesis indicates patients coinciding in the two CTs. The number of patients exceeding 
a 10% difference is larger in VD than in Dmean. In the majority of cases, patients with values 
above 10% in VD are not necessarily the same patients in whom Dmean was increased. These 
specific OARs should be contoured and monitored in order to know if the initial plan remains 
suitable during the course of the treatment. 
To correct the effect of anatomical changes over dose distribution during the treatment, an 
adaptive radiotherapy (ART) approach is used. Schwartz and Dong(25) have reviewed current 
investigations of ART in HNC, and conclude that ART remains an unsolved problem because 
the optimal frequency, utilization, and clinical impact of ART remain undefined. Moreover, 
advances in automated planning techniques based on deformable image registration will help to 
improve the feasibility of ART in HNC patients. ART and deformable image registration are still 
in development and are, therefore, not clinically implemented in the majority of hospitals. 
Although replanning during the course of treatment is a time-consuming process, it has po-
tential advantages and is readily accessible for many centers. It should be stressed that it will be 
necessary to identify which patients in particular would benefit from replanning. For instance Ahn 
et al.(18) indicated that only 15 out of 23 patients (65%) benefitted from a new plan. Recently, 
Zhao et al.(26) showed that nasopharyngeal carcinoma patients who have clinically identified 
anatomic changes during the course of IMRT might potentially benefit from replanning.
For now, if ART rationale were used, the benefit of replanning would have to be analyzed 
individually. There are many issues which could determine the need for a replan: clinical 
patient conditions, and percentages of initial dose distribution variations for each PTV and 
OARs. The decision to consider suitable dose distribution is always a compromise between 
dose in target volumes and dose in OARs. Furthermore, both facilities and human/economi-
cal resources could determine the final decision for replanning. These complex factors are 
beyond the scope of this work but until now, no predictive factors that might identify the need 
for replanning have been reported. It is therefore essential to establish a rational adaptive RT 
scheme compliant with defined dosimetric criteria. The dosimetric criteria employed to select 
which patients could benefit most from replanning should be based on the knowledge of spa-
tial dose variations on both target volumes and organs at risk during the course of treatment. 
Dose variations reported in our study may therefore be of some help for future investigations 
concerning adaptive radiotherapy.
 
Table 5. Dose variation range of Dmean and VD, for the oral cavity, lips, and middle lower neck, and number of patients 
with dose increase up to 10%.
 Dmean (%) VD (%)
a 
   Patients with dose   Patients with dose
Normal Structure  Range increase up 10% Range increase up 10
Oral Cavity CT15 -2.5, 6.2  0 -7.4, 22.2 4
D =40 Gy CT25 -2.4, 10.9 1 -5.1, 21 2 (1)
Middle low neck CT15 -1, 9.6 0 -1.8, 16.3  4 
D = 40 Gy CT25 -2.3, 8.8  0 -17.7, 19.3 3 (0)
Lips CT15 -3.4, 14.5  2 -12.1,  29 5 
D = 20 Gy CT25 -0.5, 14.9 3 (1) -2.5, 29 3 (3)
a VD means percentage of total volume receiving a D dose. 
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V. concLuSIonS
Variations in patient positioning and anatomical changes during IMRT for head-and-neck 
cancer can modify dosimetric parameters and may therefore have clinical implications on lo-
cal control and toxicity. We have seen that the dose distribution over target volumes shows a 
decrease of coverage in the first part of the treatment and an overdosage towards the final part 
of the treatment. The mean dose in the parotid glands showed significant increases both for the 
contralateral than ipsilateral parotid gland. The present work has included structures related 
with new IMRT toxicities with the oral cavity, lips, brain, and lower middle neck irradiation. 
It is, to our knowledge, the first study analyzing the influence of volume changes over dose 
distribution on these particular organs at risk. Results have shown that there is a significant 
dose increase in the oral cavity, lips, and lower middle neck, although these structures did not 
present volume variations. 
Behavior of dose distribution over target volumes and OARs depends on several aspects, 
namley particular volume changes, localization, and the irradiation technique employed. The 
IMRT technique implies the irradiation of a larger number of OARs than conventional 3D CRT, 
some of them at high doses. In conclusion, appropriate OARs have to be contoured and monitored 
in order to know if the initial plan remains suitable during the course of the treatment. Reported 
dosimetric data can help to identify patients who could benefit from adaptive radiotherapy
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